Incorporating CDK 4/6 Inhibitors in the Treatment of Estrogen Receptor–Positive Breast Cancer: Considerations for Nurses, Patients, and Families
This activity contains:
- CNE-Certified Live Grand Rounds
- Downloadable Slide Deck (a non-certified educational resource)
The goal of this activity is to provide oncology nurses with the most recent information regarding the use of CDK 4/6 inhibitors for the treatment of patients with ER+ breast cancer.
The American Cancer Society estimated that in 2016 there were 249,260 new cases of breast cancer and 40,890 deaths due to breast cancer in the United States. Many of these patients have breast cancer that is estrogen receptor (ER) positive. Endocrine therapy is the cornerstone of treatment for advanced ER-positive breast cancer. However, not all advanced ER-positive breast cancers respond to first-line endocrine therapy, and those that do respond eventually relapse. The need for alternative therapies is especially compelling for patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer: nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and, therefore, are not candidates for HER2-targeting therapies.
Significant advances include the development of agents that target critical pathways involved in resistance to endocrine therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitors.
This activity will provide the latest information regarding CDK 4/6 inhibitors, including their mechanism of action, key clinical trial data, adverse event management, and patient education.
- Activity Overview
- The Evolving Role of the Nurse in the Treatment Decision-Making Process for Patients With Breast Cancer
- Overview of Estrogen Receptor–Positive Breast Cancer
- CDK 4/6 Inhibitors
- Integrating CDK 4/6 Inhibitor Therapy Into the Overall Treatment Plan
- Interactive Case Challenges
- Activity Conclusion and Q&A
This activity is intended for oncology nurses who manage breast cancer.
At the conclusion of this activity, participants should be better able to:
- Describe the mechanism of action of cyclin-dependent kinase 4/6 inhibitors in the setting of estrogen receptor–positive breast cancer, and the rationale for these agents
- Discuss the risks and benefits of cyclin-dependent kinase 4/6 inhibitors for the treatment of estrogen receptor–positive, HER2-negative advanced breast cancer
- Implement a plan for monitoring and managing adverse events that may occur with cyclin-dependent kinase 4/6 inhibitor therapy, in conjunction with the healthcare team, patients, and families
|Theresa W. Gillespie, PhD, MA, RN|
Professor, Department of Surgery and Department of
Hematology & Medical Oncology
Emory University School of Medicine, and
Winship Cancer Institute and
Nell Hodgson Woodruff School of Nursing
Jeannine M. Brant, PhD, APRN, AOCN, FAAN
Jacquelyn Lauria, MS, RN, APN, AOCNP
|Kelley D. Mayden, MSN, FNP, AOCNP|
Oncology Nurse Practitioner
Wellmont Cancer Institute
|Lisa Moss, MS, AOCNP |
Adult Nurse Practitioner
Virginia Commonwealth University
Division of Hematology/Oncology and Palliative Care
|Kristi K. Orbaugh, MSN, RNP, AOCN|
Indiana Community Cancer Care
|Debra L. Winkeljohn, MSN, RN, CNS, AOCN®|
CNS Research Nurse
Hematology Oncology Associates
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.
Iowa Board of Nursing
AXIS is Iowa Board of Nursing Approved Provider Number 371, for 1.0 contact hour.
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Theresa W. Gillespie, PhD, MA, RN||Theresa W. Gillespie, PhD, MA, RN, APRN-CNS, AOCN®, reported a financial interest/relationship or affiliation in the form of Research grant, HIH, November Foundation, PCORI|
|Jeannine M. Brant, PhD, APRN, AOCN®, FAAN|
Jeannine M. Brant, PhD, APRN-CNS, FAAN, AOCN®, reported a financial interest/relationship or affiliation in the form of Speakers' Bureau, Genentech, Inc, Insys
|Jacquelyn Lauria, MS, RN, APN, AOCNP||Jacquelyn Lauria, MS, RN, APN, AOCNP has no real or apparent conflicts of interest to report.|
|Kelley Mayden, MSN, FNP, AOCNP||Kelley Mayden, MSN, FNP, AOCNP reported a financial interest/relationship or affiliation in the form of Speakers' bureau Takeda Pharmaceuticals, Apobiologix, and Puma Biotechnology.|
|Lisa Moss, MS, AOCNP||Lisa Moss, MS, AOCNP reported a financial interest/relationship or affiliation in the form of Speakers' bureau, Celegene.|
|Kristi K. Orbaugh, MSN, RNP, AOCN®||Kristi K. Orbaugh, MSN, RN, RNP, AOCN®, reported a financial interest/relationship or affiliation in the form of Speakers' bureau, Novartis Pharmaceuticals Corp, Pfizer, Inc, Teva Pharmaceuticals, Bristol-Myers Squibb Co|
|Debra L. Winkeljohn, MSN, RN, CNS, AOCN®||Debra L. Winkeljohn, MSN, RN, CNS, AOCN®, has no real or apparent conflicts of interest to report.|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda Gracie-King, MS; Ronald Viggiani, MD; Jocelyn Timko, BS; Marilyn Haas, PhD, RN, CNS, ANP-BC; hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
This activity is supported by educational grants from Novartis Pharmaceuticals and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
There is no fee for this educational activity.
This activity is provided by:
- 1.00 ANCC
- 1.00 Attendance